Press Releases

Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025

Jul 29, 2025

Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 2, 2025

Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

Jun 30, 2025

Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

Jun 25, 2025

Iterum Therapeutics Announces Partnership for Commercialization Services

Jun 11, 2025

Iterum Therapeutics Announces Extension of Term of Promissory Note

May 19, 2025

Iterum Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025

Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025

May 6, 2025

Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares

Apr 30, 2025

Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares

Apr 29, 2025